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Abstract: Antifungal resistance is a topic of concern, particularly for specific fungal species and drugs.
Among these are the multidrug-resistant Candida auris and azole-resistant Aspergillus fumigatus. While
the knowledge on molecular mechanisms of resistance is now accumulating, further data are also
available for the clinical implications and the extent of correlation of in vitro resistance to clinical
outcomes. This review article summarizes the epidemiology of C. auris infections, animal models
focusing on the activity of novel antifungal compounds in C. auris infections, virulence factors,
and the mechanisms of antifungal resistance for this multi-resistant Candida species. Regarding A.
fumigatus, the significance of azoles in the treatment of A. fumigatus infections, reference methods
available for the detection of resistance in vitro, molecular mechanisms of secondary azole resistance,
routes of acquisition, and clinical implications of in vitro resistance are covered to provide guidance
for the current status of azole resistance in A. fumigatus.
Keywords: Candida auris; Aspergillus fumigatus; antifungal resistance; multidrug resistance;
mechanisms of antifungal resistance
1. Candida auris
1.1. Epidemiology and Risk Factors for Candida auris Infection
Nosocomial infections with resistant Candida species are increasing and candidemia is becoming
a public health concern in Europe, the Americas, and Asia. This is associated with increasing numbers
of immunocompromised individuals, the rampant empirical use of broad-spectrum antibiotics
and fluconazole, and the widespread use of implanted medical devices. Invasive non-albicans
candidiasis was mainly reported, until recently, due to C. glabrata, C. parapsilosis, C. tropicalis, and
Pichia kudriavzevii (C. krusei). C. parapsilosis is common among newborns, while C. glabrata is more
prevalent among older adults and patients with cancer. C. tropicalis, on the other hand, is more
commonly seen in patients with leukemia and neutropenia. C. parapsilosis, a skin colonizer, is a
common pathogen in intravascular catheter-related infections. Pichia kudriavzevii, in turn, is found
more often among patients with leukemia and associated neutropenia, who receive fluconazole
prophylaxis [1]. A new species, C. auris, associated with resistance to several antifungal drugs
and difficulty in identification, has been observed to be emerging in the last decade. This yeast
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was first described in East Asia in 2009, after being isolated from a Japanese patient with otitis
externa and three Korean patients with candidemia [2,3]. These observations did not attract much
attention from the medical community at the time until clonal outbreaks were observed in several
Indian hospitals [4,5]. Shortly after these seminal publications, reports followed from Kuwait, South
Africa, and Venezuela [6–10]. C. auris, which was never heard of prior to the first publication in
2009, became an emerging global health threat with outbreaks occurring in many health facilities.
It is highly likely that C. auris was an underreported infection in the first years after 2009 due to
difficulties in identification [11–16]. At present, infected and colonized patients have been identified
in Australia [17], Austria [18], Belgium [19], Canada [20], China [21–23], Colombia [24,25], Egypt
(unpublished), France [19], Germany [19], India [4,26–29], Iran (unpublished), Israel [30,31], Kenya [15],
Kuwait [7,9,10], Korea [3,32], Malaysia [33], the Netherlands [15], Norway [19], Oman [34,35],
Pakistan [36], Panama [37], Russia [15], Saudi Arabia [38], Singapore [39], South Africa [8,40],
Spain [41], Switzerland [42], Thailand [15], United Kingdom [43–46], United States [36,47], United
Arab Emirates [48], and Venezuela [6]. More than 4000 cases of infection and colonization, the majority
from India and South Africa, have been recorded to date, but it is highly likely that we are observing
only the tip of the iceberg.
C. auris is a novel Candida species in the Candida haemulonii species complex, which causes a
wide range of infections, especially in debilitated patients residing in intensive care units (ICUs).
A large 18-month prospective study in Indian ICUs recorded 1400 candidemia cases; C. auris was
identified as the fifth most common cause found in 19 out of 27 ICUs, with a prevalence of 5.3% [27].
In some tertiary care Indian hospitals, C. auris is the second most common cause of candidemia after C.
tropicalis [49]. A tertiary medical center in South America reported C. auris as the sixth most common
cause of nosocomial bloodstream infections between March 2012 and July 2013 [6]. The mode of
spread within the hospital setting is through person to person transmission and via contaminated
surfaces and/or equipment. During outbreaks, C. auris can contaminate the room of colonized or
infected patients [50]. It is therefore of utmost importance to quickly identify contaminated surfaces
and screen specimens of patients. Real-time detection and identification of C. auris is the target of
several molecular kits [51–59]. The survival of C. auris for weeks, even months, within the hospital
confirms the importance of infection prevention programs [60–62]. Transmission from patient to
patient has been documented to lead to skin colonization by C. auris and increased risk for candidemia.
The hospital environment represents a reservoir that contributes to the nosocomial transmission of
C. auris similar to that seen with multi-resistant bacterial pathogens [63,64]. Risk factors for infection
with C. auris are related to immunosuppression, hospitalization in intensive care units over prolonged
periods, use of central venous and urinary catheters, and empirical use of antibiotics or antifungals.
Adults are mainly affected, but in an outbreak situation in Venezuela 13/18 cases were pediatric
patients [6]. As observed in many other studies, all isolates were initially mis-identified as Candida
haemulonii, a commonly reported mistake [65–67]. Sequencing of the internal transcribed spacer
(ITS) region and MALDI-TOF analysis were necessary to identify isolates of the outbreak involved
as C. auris. The predisposing risk factors for C. auris infection are similar to other opportunistic
Candida species [1]; that is, immunocompromised patients (diabetes mellitus, malignancy, chronic
renal disease, neutropenia, HIV), concomitant bacteremia, broad spectrum antibacterial or antifungal
therapy within 90 days, surgery within 90 days, presence of central venous catheters or urinary
catheters, ICU stay, and parenteral nutrition (PN) administration confer an increased risk of acquiring
C. auris. A case-control study in an Indian center was conducted to determine specific risk factors
predisposing to C. auris candidemia [29]. Patients with C. auris (n = 74) and non-auris (n = 1087)
fungemia cases were analyzed. Multivariate analysis showed that patients with respiratory diseases,
vascular surgery, and prolonged exposure to fluconazole were more likely to develop ICU-onset C. auris
fungemia. In describing the epidemiology of C. auris infections, the Center for Disease Control (CDC)
used whole genome sequencing of 54 isolates collected from India, Pakistan, South Africa, Japan, and
Venezuela [36]. Four distinct geographical clades were observed, suggesting emergence at the same
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time on three continents. Similar geographic clustering was observed with Amplified Fragment Length
Polymorphism(AFLP) and proteomic analysis of C. auris isolates from three different continents—Asia,
Africa, and Latin America [68]. A recent Whole Genome Sequencing (WGS) and single-nucleotide
polymorphism (SNP) analysis of C. auris strains isolated in the USA showed multiple introductions
of C. auris isolates belonging to the four clades, and spread among healthcare facilities [47]. Most
C. auris strains (>60–90%) are resistant to fluconazole, 10–30% exhibit a high minimum inhibitory
concentration (MIC) for amphotericin B, and <5% can be considered resistant to echinocandins [28,69].
Given the recent unprecedented worldwide spread and multidrug resistance, C. auris is included in
the world’s 10 most feared fungi [70].
1.2. Virulence Factors of C. auris
To determine the virulence properties of C. auris relative to C. albicans, a set of clinical strains
were investigated regarding the ability to germinate, adhere, and produce extracellular enzymes [71].
C. auris strains failed to germinate but, in contrast and as expected, C. albicans germinated profusely.
Similarly, C. auris exhibited a significantly reduced ability to adhere to silicon elastomer disks relative to
C. albicans. Moreover, the C. auris isolates produced phospholipase and proteinase in a strain-dependent
manner (37.5% of the C. auris strains possessed phospholipase activity, while 64% evaluated secreted
proteinase activity). The last virulence factor evaluated was the ability of C. auris to form biofilms.
Our data showed that the formed biofilms were mainly composed of yeast cells, while biofilms formed
by C. albicans had a heterogeneous architecture of biofilms comprised of yeast and hyphae morphology
embedded within the extracellular matrix. Furthermore, C. auris biofilms had a limited amount of
extracellular matrix relative to C. albicans and its biofilm thickness was significantly less than the
biofilms formed by C. albicans. Taken together, these data show that C. auris is relatively less pathogenic
than C. albicans.
1.3. C. auris Animal Models and Activity of Experimental Antifungals
To gain insight into the in vivo virulence of C. auris, an immunosuppressed murine model
was developed [72,73]. Once the model was established it was used to evaluate the efficacy of
two experimental antifungals (rezafungin and APX001A). The data showed that rezafungin had
a significantly reduced CFUs/g kidneys fungal burden compared with vehicle- or amphotericin
B-treated groups. Furthermore, treatment with rezafungin resulted in a significantly lower CFUs/g
tissue fungal burden compared to micafungin-treated animals [72].
Evaluation of the efficacy of APX001 using the optimized immunocompromised mouse model
showed that treatment with this experimental drug resulted in a significant increase in animal
survival (between 80 and 100% survival in the three treatment groups). In contrast, treatment with
anidulafungin led to only a 50% survival rate. In addition, APX001 treatment led to a significant
reduction in CFUs/g of kidneys, lung, and brain tissue compared to the vehicle-treated group [73].
In an immunocompetent murine model, virulence was also highest for C. albicans, closely followed by
C. auris, C. glabrata, and C. haemulonii, respectively [74].
1.4. Resistance of C. auris
Besides being antifungal-resistant, C. auris is thermotolerant, grows well up to 42 ◦C, and is
salt-tolerant (up to 10%). These characteristics can be used to design selective media for the detection
of C. auris for screening purposes which have been used successfully in outbreak investigations [75].
Concerning resistance to antifungal agents, C. auris has demonstrated extensive resistance to azoles
and amphotericin B [24,28]. The ATP-binding cassette (ABC) transporter activity was significantly
higher in C. auris than in C. glabrata [31]. Several genes show encoding of ABC transporters and the
important families of C. auris major facilitator superfamily (MFS) genes [76]. An Indian study with a
large number of isolates showed that 41% of C. auris from India showed resistance to two antifungal
classes and 4% to three antifungal agents [28]. Molecular mechanisms responsible for antifungal
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resistance point to efflux pumps and mutations in the lanosterol 14-alpha-demethylase (ERG11) gene
to explain the high rate of resistance to fluconazole [28,31]. The latter study demonstrated that 90% of
C. auris isolates were resistant to fluconazole (MICs 32 to ≥64 mg/L). ERG11 sequences of resistant
C. auris exhibited substitutions of the Y132 and K143 amino acids in 77% of the fluconazole-resistant
strains. No substitutions at these positions were observed in isolates with low fluconazole MICs
(1–2 mg/L), suggesting that these substitutions confer the fluconazole resistance phenotype similar to
that described for C. albicans [77].
Another study, in a murine model, showed that micafungin was superior compared to fluconazole
or amphotericin B, with greater fungicidal activity [78]. These findings make echinocandins the drugs
of choice to treat C. auris infections and clinical trials are on their way to explore the therapeutic
potential of new drugs.
The combination of antifungals such as voriconazole and echinocandins has been shown to be
promising in vitro against resistant C. auris [79]. Although some studies show variable susceptibility of
C. auris to the echinocandin class [80], the good news is that there are new drugs in development with
excellent activity against C. auris [71–73,81–85]. SCY-078, a novel orally bioavailable 1,3-β-D-glucan
synthesis inhibitor, has been shown to exhibit both in vitro and in vivo activity against C. auris,
including some echinocandin-resistant isolates. VT-1598 is another new azole drug with broad activity
including C. auris isolates (MIC range 0.03–8 mg/L) [86,87].
The cleaning and terminal disinfection of rooms where C. auris-colonized patients have been
problematic [61,88]. Moore et al. [89] showed that chlorine-based disinfectants and iodine-based
skin antiseptics were effective against C. auris and reduced environmental contamination and skin
colonization. Chlorhexidine-based products may also be effective. Abdolrasouli and collaborators [90]
demonstrated that C. auris isolates were inhibited by chlorhexidine gluconate at 0.125–1.5% and by
iodinated povidone at a concentration of 0.07–1.25%.
2. Aspergillus fumigatus
2.1. Azole Resistance in A. fumigatus
Aspergillus remains significant as one of the causative agents of invasive infections in
immunocompromised individuals and frequently constitutes the most common mold genus isolated in
this setting. While voriconazole is the primary drug of choice in the treatment of invasive aspergillosis,
the emergence of azole resistance in Aspergillus has been a concern since the first report of secondary
resistance of A. fumigatus to itraconazole in 1997 [91,92]. Antifungal drugs which exert activity
against Aspergillus spp. are amphotericin B, triazoles, and echinocandins. Furthermore, triazoles
are of particular significance due to the availability of oral formulations. Based on this, triazoles
constitute significant therapeutic options for patients with chronic pulmonary aspergillosis and
allergic bronchopulmonary aspergillosis who require long-term therapy [93] and azole resistance
in A. fumigatus is thus a concern in this respect as well.
Secondary azole resistance in A. fumigatus has been reported from many countries and centers in
six continents at extensively varying rates. Similar to those for strains isolated from clinical samples,
resistance rates detected for environmental strains are also diverse [94–101]. The ISHAM/ECMM
Aspergillus Resistance Surveillance Working Group aims to facilitate surveillance studies to determine
resistance epidemiology in countries where data are currently lacking and provide further insight in
terms of clinical implications [102].
While secondary azole resistance in A. fumigatus draws remarkable attention, the awareness and
knowledge on primary antifungal resistance in Aspergillus strains are also increasing. Among the
species which are relatively common causes of invasive infections and exhibit primary resistance or
reduced susceptibility to one or more antifungal drugs are Aspergillus lentulus (resistance to azoles and
amphotericin B and varied susceptibility to caspofungin), Aspergillus flavus (reduced susceptibility to
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amphotericin B and varied susceptibility to caspofungin), Aspergillus alliaceus (reduced susceptibility
to amphotericin B and caspofungin), and Aspergillus terreus (resistance to amphotericin B) [96].
2.2. Detection of Antifungal Resistance In Vitro by Reference Methods
Reference CLSI [103] and EUCAST [104,105] microdilution susceptibility testing methods are
available for testing antifungal drugs against Aspergillus and recommended for routine use [106,107].
A disk diffusion method of CLSI for testing non-dermatophyte molds and thus applying also to
Aspergillus is also available [108]. Epidemiological cut-off values have been determined for the
interpretation of the results obtained by the CLSI method [109–112], while both epidemiological
cut-off values and clinical breakpoints are available for interpreting EUCAST minimum inhibitory
concentration values (MIC, mg/L) for some drugs and species [113]. The official reading method
for amphotericin B and azole MICs against Aspergillus is visual reading for both CLSI and EUCAST
methodologies. A spectrophotometric reading alternative for EUCAST amphotericin B and azole
MICs at 5% growth cut-off (vs. complete inhibition of growth visually) proved to be a reliable
alternative [105].
An agar screening method for the detection of secondary azole resistance in A. fumigatus strains has
also been validated recently by a multicenter study undertaken by EUCAST [114]. This method uses
(in-house or commercially available) 4-well agar plates containing itraconazole (4 mg/L), voriconazole
(2 mg/L), and posaconazole (0.5 mg/L); the fourth well serves as the growth control well without any
antifungal drug. The ranges of 80–100% and 97–100% were obtained, respectively, for interobserver
agreement rate and overall sensitivity. The inter-plate (in-house vs. commercial) agreement rate was
high. Similarly, the sensitivity for simulated mixed samples of wild-type and mutant strains and the
overall specificity rates also proved to be acceptably high (83–100% and 95–100%, respectively). Based
on these data, the assay was validated and is now available as a reference method as documented
in EUCAST E.DEF 10.1 [115]. It is an easy and reliable method recommended to be used for routine
laboratory work-up, to be followed by reference MIC testing for confirmation in case of the detection
of a resistant strain [106].
2.3. Molecular Mechanisms Involved in Secondary Azole Resistance and the Resulting Azole Susceptibility Profiles
Point mutations in the cyp51A gene associated with amino acid changes of M220, G54, G138,
G448S, as well as L98H are the most common mechanisms of secondary azole resistance in A. fumigatus.
Extra copies of the cyp51A gene (e.g., tandem repeats of a 34- or 46-bp sequence in the promoter of
the cyp51A gene) may also accompany specific amino acid changes. The typical examples of this
combined pattern are TR34/L98H and TR46/Y121F/T289A [116]. A tandem repeat of 53 bp without
any accompanying amino acid change has also been described [117,118]. In addition, non-cyp51
mutations and increased expression of efflux pumps may play a role in the development of secondary
azole resistance. On the other hand, the mechanism remains unknown for a number of isolates.
The expected azole susceptibility profiles in relation to the associated amino acid changes and/or
tandem repeats are summarized in Table 1 [95,116].
Table 1. Expected azole susceptibility profiles with respect to the detected resistance mechanism(s).
Associated Amino Acid
Change/Tandem Repeat Resistance Reduced Susceptibility Variable Susceptibility Profile
G54 ITC, POS
G138 ITC, POS
G448S VRC ITC, POS
M220 ITC VRC POS
TR34/L98H * ITC, VRC, POS, ISV
TR46/Y121F/T289A VRC ITC, POS
TR53 ITC, VRC POS
ISV: isavuconazole; ITC: itraconazole; POS: posaconazole; VRC: voriconazole; *: Isolates with
TR34/L98H/S297T/F495I changes may have lower minimum inhibitory concentrations (MICs) of voriconazole in
the wild-type range. The S297T mutation might be a compensatory mutation in these cases [119,120].
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2.4. Acquisition of Secondary Azole Resistance
There are two mechanisms that play a role in the development of secondary azole resistance in
A. fumigatus. First is the (long-term) azole therapy in an individual patient with chronic pulmonary
lung disease mostly in existence of a pulmonary cavity, and second is the direct acquisition of
a resistant strain from the environment. The latter develops due to the use of azole fungicides
(penconazole, difenoconazole, tetraconazole, and tebuconazole) in the environment in agriculture for
plant protection [98,121]. The molecular mechanisms leading to resistance also differ in general for
these two routes of acquisition. In the patient-acquired route, M220, G54, and G138 changes are more
common while TR34/L98H and TR46/Y121F/T289A patterns are mostly (but not always) observed
following environmental acquisition [95,116].
2.5. Clinical Implications and Current Recommendations for Treatment of Aspergillosis due to Azole-Resistant
A. fumigatus
While high azole MICs [122,123] or the existence of cyp51A mutations [124] were found to
be correlated with clinical failure in some studies, other investigators were not able to detect any
correlation between MICs and survival rates [125]. This may also emphasize the influence of host
factors as well as several others on clinical outcomes in invasive fungal infections observed in
immunocompromised individuals. The low rates of resistance, i.e., the low number of infections due to
azole-resistant strains included in the analysis, may also render it more difficult to detect any possibly
existing in vitro–in vivo correlation. “Strong” or “Moderate” recommendations for the treatment of
documented azole-resistant aspergillosis, as included in the recently published ESCMID-ECMM-ERS
Guideline [106], are liposomal amphotericin B monotherapy (Strength of Recommendation (SoR) and
Quality of Evidence (QoE): AIIu) and voriconazole and anidulafungin combination (BIII), respectively.
Other options with a “Marginal” level of recommendation (CIII for all noted alternatives) include
amphotericin B lipid complex monotherapy, posaconazole and caspofungin combination, caspofungin
or micafungin monotherapy. The expert opinion, on the other hand, recommends a modification
in primary therapeutic choice of voriconazole in case of local environmental resistance rates of
>10%. Voriconazole and echinocandin combination or liposomal amphotericin B monotherapy is
recommended for initial therapy under these settings [126].
3. Concluding Remark
The emerging field of molecular mechanisms of antifungal resistance has been an underestimated
area of global public health concern, but significant progress has been made lately in A. fumigatus and
C. auris, although research challenges remain formidable.
Author Contributions: S.A.-A., M.G. and J.F.M. prepared the manuscript.
Funding: This research received no external funding.
Conflicts of Interest: JFM reports grants from F2G, Merck and Pulmozyme, consultancy fees from Scynexis and
speaker fees from Merck, United Medical, Gilead Sciences and TEVA, outside the submitted work. MAG declares
receiving grants, and/or acting as a consultant for the following companies: Scynexis, Amplyx, Cidara, and F2G.
SAA reports investigator-initiated research grant from Pfizer and lecture honoraria from Astellas, Gilead, Merck,
and Pfizer, outside the submitted work.
References
1. Pappas, P.G.; Lionakis, M.S.; Arendrup, M.C.; Ostrosky-Zeichner, L.; Kullberg, B.J. Invasive candidiasis.
Nat. Rev. Dis. Primers 2018, 4, 18026. [CrossRef] [PubMed]
2. Satoh, K.; Makimura, K.; Hasumi, Y.; Nishiyama, Y.; Uchida, K.; Yamaguchi, H. Candida auris sp. nov.,
a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital.
Microbiol. Immunol. 2009, 53, 41–44. [CrossRef] [PubMed]
3. Lee, W.G.; Shin, J.H.; Uh, Y.; Kang, M.G.; Kim, S.H.; Park, K.H.; Jang, H.C. First three reported cases of
nosocomial fungemia caused by Candida auris. J. Clin. Microbiol. 2011, 49, 3139–3142. [CrossRef] [PubMed]
J. Fungi 2018, 4, 129 7 of 13
4. Chowdhary, A.; Sharma, C.; Duggal, S.; Agarwal, K.; Prakash, A.; Singh, P.K.; Jain, S.; Kathuria, S.;
Randhawa, H.S.; Hagen, F.; et al. New clonal strain of Candida auris, Delhi, India. Emerg. Infect. Dis.
2013, 19, 1670–1673. [CrossRef] [PubMed]
5. Chowdhary, A.; Sharma, C.; Meis, J.F. Candida auris: A rapidly emerging cause of hospital-acquired
multidrug-resistant fungal infections globally. PLoS Pathog. 2017, 13, e1006290. [CrossRef] [PubMed]
6. Calvo, B.; Melo, A.S.; Perozo-Mena, A.; Hernandez, M.; Francisco, E.C.; Hagen, F.; Meis, J.F.; Colombo, A.L.
First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia.
J. Infect. 2016, 73, 369–374. [CrossRef] [PubMed]
7. Emara, M.; Ahmad, S.; Khan, Z.; Joseph, L.; Al-Obaid, I.; Purohit, P.; Bafna, R. Candida auris candidemia in
Kuwait, 2014. Emerg. Infect. Dis. 2015, 21, 1091–1092. [CrossRef]
8. Magobo, R.E.; Corcoran, C.; Seetharam, S.; Govender, N.P. Candida auris-associated candidemia, South Africa.
Emerg. Infect. Dis. 2014, 20, 1250–1251. [CrossRef]
9. Khan, Z.; Ahmad, S.; Al-Sweih, N.; Joseph, L.; Alfouzan, W.; Asadzadeh, M. Increasing prevalence, molecular
characterization and antifungal drug susceptibility of serial Candida auris isolates in Kuwait. PLoS ONE 2018,
13, e0195743. [CrossRef]
10. Khan, Z.; Ahmad, S.; Benwan, K.; Purohit, P.; Al-Obaid, I.; Bafna, R.; Emara, M.; Mokaddas, E.;
Abdullah, A.A.; Al-Obaid, K.; et al. Invasive Candida auris infections in Kuwait hospitals: epidemiology,
antifungal treatment and outcome. Infection 2018, 46, 641–650. [CrossRef]
11. Bidaud, A.L.; Chowdhary, A.; Dannaoui, E. Candida auris: An emerging drug resistant yeast-A mini-review.
J. Mycol Med. 2018, 28, 568–573. [CrossRef] [PubMed]
12. Clancy, C.J.; Nguyen, M.H. Emergence of Candida auris: An international call to arms. Clin. Infect. Dis. 2017,
64, 141–143. [CrossRef] [PubMed]
13. Forsberg, K.; Woodworth, K.; Walters, M.; Berkow, E.L.; Jackson, B.; Chiller, T.; Vallabhaneni, S. Candida auris:
The recent emergence of a multidrug-resistant fungal pathogen. Med. Mycol. 2018. [CrossRef] [PubMed]
14. Jeffery-Smith, A.; Taori, S.K.; Schelenz, S.; Jeffery, K.; Johnson, E.M.; Borman, A.; Candida auris Incident
Management, T.; Manuel, R.; Brown, C.S. Candida auris: a Review of the literature. Clin. Microbiol. Rev. 2018,
31, e00029-17. [CrossRef] [PubMed]
15. Saris, K.; Meis, J.F.; Voss, A. Candida auris. Curr Opin Infect. Dis. 2018, 31, 334–340. [CrossRef] [PubMed]
16. Tsay, S.; Kallen, A.; Jackson, B.R.; Chiller, T.M.; Vallabhaneni, S. Approach to the investigation and
management of patients with Candida auris, an emerging multidrug-resistant yeast. Clin. Infect. Dis.
2018, 66, 306–311. [CrossRef]
17. Heath, C.H.; Dyer, J.R.; Pang, S.; Coombs, G.W.; Gardam, D.J. Candida auris sternal osteomyelitis diagnosis in
man from Kenya visiting Australia, 2015. Emerg. Infect. Dis. 2019, 25. (in press).
18. Pekard-Amenitsch, S.; Schriebl, A.; Posawetz, W.; Willinger, B.; Kolli, B.; Buzina, W. Isolation of Candida auris
from Ear of Otherwise Healthy Patient, Austria, 2018. Emerg. Infect. Dis. 2018, 24, 1596–1597. [CrossRef]
19. Kohlenberg, A.; Struelens, M.J.; Monnet, D.L.; Plachouras, D.; The Candida Auris Survey Collaborative, G.
Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and
European Economic Area countries, 2013 to 2017. Euro Surveill 2018, 23. [CrossRef]
20. Schwartz, I.S.; Hammond, G.W. First reported case of multidrug-resistant Candida auris in Canada.
Can. Commun Dis. Rep. 2017, 43, 150–153. [CrossRef]
21. Chen, Y.; Zhao, J.; Han, L.; Qi, L.; Fan, W.; Liu, J.; Wang, Z.; Xia, X.; Chen, J.; Zhang, L. Emergency of
fungemia cases caused by fluconazole-resistant Candida auris in Beijing, China. J. Infect. 2018. [CrossRef]
22. Tian, S.; Rong, C.; Nian, H.; Li, F.; Chu, Y.; Cheng, S.; Shang, H. First cases and risk factors of super yeast
Candida auris infection or colonization from Shenyang, China. Emerg. Microbes Infect. 2018, 7, 128. [CrossRef]
[PubMed]
23. Wang, X.; Bing, J.; Zheng, Q.; Zhang, F.; Liu, J.; Yue, H.; Tao, L.; Du, H.; Wang, Y.; Wang, H.; et al. The first
isolate of Candida auris in China: clinical and biological aspects. Emerg. Microbes Infect. 2018, 7, 93. [CrossRef]
[PubMed]
24. Escandon, P.; Chow, N.A.; Caceres, D.H.; Gade, L.; Berkow, E.L.; Armstrong, P.; Rivera, S.; Misas, E.;
Duarte, C.; Moulton-Meissner, H.; et al. Molecular epidemiology of Candida auris in Colombia
reveals a highly-related, country-wide colonization with regional patterns in Amphotericin B resistance.
Clin. Infect. Dis. 2018. [CrossRef] [PubMed]
J. Fungi 2018, 4, 129 8 of 13
25. Morales-Lopez, S.E.; Parra-Giraldo, C.M.; Ceballos-Garzon, A.; Martinez, H.P.; Rodriguez, G.J.;
Alvarez-Moreno, C.A.; Rodriguez, J.Y. Invasive infections with multidrug-resistant yeast Candida auris,
Colombia. Emerg. Infect. Dis. 2017, 23, 162–164. [CrossRef] [PubMed]
26. Biswal, M.; Rudramurthy, S.M.; Jain, N.; Shamanth, A.S.; Sharma, D.; Jain, K.; Yaddanapudi, L.N.;
Chakrabarti, A. Controlling a possible outbreak of Candida auris infection: lessons learnt from multiple
interventions. J. Hosp. Infect. 2017, 97, 363–370. [CrossRef] [PubMed]
27. Chakrabarti, A.; Sood, P.; Rudramurthy, S.M.; Chen, S.; Kaur, H.; Capoor, M.; Chhina, D.; Rao, R.;
Eshwara, V.K.; Xess, I.; et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India.
Intensive Care Med. 2015, 41, 285–295. [CrossRef] [PubMed]
28. Chowdhary, A.; Prakash, A.; Sharma, C.; Kordalewska, M.; Kumar, A.; Sarma, S.; Tarai, B.; Singh, A.;
Upadhyaya, G.; Upadhyay, S.; et al. A multicentre study of antifungal susceptibility patterns among 350
Candida auris isolates (2009–17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin
resistance. J. Antimicrob. Chemother. 2018, 73, 891–899. [CrossRef]
29. Rudramurthy, S.M.; Chakrabarti, A.; Paul, R.A.; Sood, P.; Kaur, H.; Capoor, M.R.; Kindo, A.J.; Marak, R.S.K.;
Arora, A.; Sardana, R.; et al. Candida auris candidaemia in Indian ICUs: analysis of risk factors.
J. Antimicrob. Chemother. 2017, 72, 1794–1801. [CrossRef]
30. Belkin, A.; Gazit, Z.; Keller, N.; Ben-Ami, R.; Wieder-Finesod, A.; Novikov, A.; Rahav, G.; Brosh-Nissimov, T.
Candida auris infection leading to nosocomial transmission, Israel, 2017. Emerg. Infect. Dis. 2018, 24, 801–804.
[CrossRef]
31. Ben-Ami, R.; Berman, J.; Novikov, A.; Bash, E.; Shachor-Meyouhas, Y.; Zakin, S.; Maor, Y.; Tarabia, J.;
Schechner, V.; Adler, A.; et al. Multidrug-resistant Candida haemulonii and Candida auris, Tel Aviv, Israel.
Emerg. Infect. Dis. 2017, 23. [CrossRef]
32. Choi, H.I.; An, J.; Hwang, J.J.; Moon, S.Y.; Son, J.S. Otomastoiditis caused by Candida auris: Case report and
literature review. Mycoses 2017, 60, 488–492. [CrossRef] [PubMed]
33. Mohd Tap, R.; Lim, T.C.; Kamarudin, N.A.; Ginsapu, S.J.; Abd Razak, M.F.; Ahmad, N.; Amran, F. A fatal
case of Candida auris and Candida tropicalis candidemia in neutropenic patient. Mycopathologia 2018, 183,
559–564. [CrossRef]
34. Al-Siyabi, T.; Al Busaidi, I.; Balkhair, A.; Al-Muharrmi, Z.; Al-Salti, M.; Al’Adawi, B. First report of Candida
auris in Oman: Clinical and microbiological description of five candidemia cases. J. Infect. 2017, 75, 373–376.
[CrossRef] [PubMed]
35. Mohsin, J.; Hagen, F.; Al-Balushi, Z.A.M.; de Hoog, G.S.; Chowdhary, A.; Meis, J.F.; Al-Hatmi, A.M.S. The
first cases of Candida auris candidaemia in Oman. Mycoses 2017, 60, 569–575. [CrossRef] [PubMed]
36. Lockhart, S.R.; Etienne, K.A.; Vallabhaneni, S.; Farooqi, J.; Chowdhary, A.; Govender, N.P.; Colombo, A.L.;
Calvo, B.; Cuomo, C.A.; Desjardins, C.A.; et al. Simultaneous emergence of multidrug-resistant Candida auris
on three continents confirmed by whole-genome sequencing and epidemiological analyses. Clin. Infect. Dis.
2017, 64, 134–140. [CrossRef] [PubMed]
37. Araúz, A.B.; Caceres, D.H.; Santiago, E.; Armstrong, P.; Arosemena, S.; Ramos, C.; Espinosa-Bode, A.;
Borace, J.; Hayer, L.; Cedeno, I.; et al. Isolation of Candida auris from nine patients in Central America:
Importance of accurate diagnosis and susceptibility testing. Mycoses 2018, 61, 44–47. [CrossRef] [PubMed]
38. Abdalhamid, B.; Almaghrabi, R.; Althawadi, S.; Omrani, A. First report of Candida auris infections from
Saudi Arabia. J. Infect. Public Health 2018, 11, 598–599. [CrossRef] [PubMed]
39. Tan, Y.E.; Tan, A.L. Arrival of Candida auris fungus in Singapore: Report of the first three cases. Ann. Acad
Med. Singapore 2018, 47, 260–262.
40. Govender, N.P.; Magobo, R.E.; Mpembe, R.; Mhlanga, M.; Matlapeng, P.; Corcoran, C.; Govind, C.;
Lowman, W.; Senekal, M.; Thomas, J. Candida auris in South Africa, 2012–2016. Emerg. Infect. Dis. 2018, 24,
2036–2040. [CrossRef]
41. Ruiz-Gaitan, A.; Moret, A.M.; Tasias-Pitarch, M.; Aleixandre-Lopez, A.I.; Martinez-Morel, H.; Calabuig, E.;
Salavert-Lleti, M.; Ramirez, P.; Lopez-Hontangas, J.L.; Hagen, F.; et al. An outbreak due to Candida auris with
prolonged colonisation and candidaemia in a tertiary care European hospital. Mycoses 2018, 61, 498–505.
[CrossRef]
42. Riat, A.; Neofytos, D.; Coste, A.; Harbarth, S.; Bizzini, A.; Grandbastien, B.; Pugin, J.; Lamoth, F. First case of
Candida auris in Switzerland: discussion about preventive strategies. Swiss Med. Wkly. 2018, 148, w14622.
[PubMed]
J. Fungi 2018, 4, 129 9 of 13
43. Borman, A.M.; Szekely, A.; Johnson, E.M. Comparative pathogenicity of United Kingdom isolates of the
emerging pathogen Candida auris and other key pathogenic Candida species. mSphere 2016, 1. [CrossRef]
[PubMed]
44. Schelenz, S.; Hagen, F.; Rhodes, J.L.; Abdolrasouli, A.; Chowdhary, A.; Hall, A.; Ryan, L.; Shackleton, J.;
Trimlett, R.; Meis, J.F.; et al. First hospital outbreak of the globally emerging Candida auris in a European
hospital. Antimicrob. Resist. Infect. Control. 2016, 5, 35. [CrossRef] [PubMed]
45. Eyre, D.W.; Sheppard, A.E.; Madder, H.; Moir, I.; Moroney, R.; Quan, T.P.; Griffiths, D.; George, S.; Butcher, L.;
Morgan, M.; et al. A Candida auris outbreak and its Control in an intensive care setting. N. Engl. J. Med. 2018,
379, 1322–1331. [CrossRef] [PubMed]
46. Rhodes, J.; Abdolrasouli, A.; Farrer, R.A.; Cuomo, C.A.; Aanensen, D.M.; Armstrong-James, D.; Fisher, M.C.;
Schelenz, S. Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida
auris. Emerg. Microbes Infect. 2018, 7, 43. [CrossRef] [PubMed]
47. Chow, N.A.; Gade, L.; Tsay, S.V.; Forsberg, K.; Greenko, J.A.; Southwick, K.L.; Barrett, P.M.; Kerins, J.L.;
Lockhart, S.R.; Chiller, T.M.; et al. Multiple introductions and subsequent transmission of multidrug-resistant
Candida auris in the USA: a molecular epidemiological survey. Lancet Infect. Dis. 2018, 18, 1377–1384.
[CrossRef]
48. Alatoom, A.; Sartawi, M.; Lawlor, K.; AbdelWareth, L.; Thomsen, J.; Nusair, A.; Mirza, I. Persistent
candidemia despite appropriate fungal therapy: First case of Candida auris from the United Arab Emirates.
Int. J. Infect. Dis. 2018, 70, 36–37. [CrossRef] [PubMed]
49. Mathur, P.; Hasan, F.; Singh, P.K.; Malhotra, R.; Walia, K.; Chowdhary, A. Five-year profile of candidaemia
at an Indian trauma centre: High rates of Candida auris blood stream infections. Mycoses 2018. [CrossRef]
[PubMed]
50. Piedrahita, C.T.; Cadnum, J.L.; Jencson, A.L.; Shaikh, A.A.; Ghannoum, M.A.; Donskey, C.J. Environmental
surfaces in healthcare facilities are a potential source for transmission of Candida auris and other Candida
species. Infect. Control. Hosp. Epidemiol. 2017, 38, 1107–1109. [CrossRef] [PubMed]
51. Yamamoto, M.; Alshahni, M.M.; Tamura, T.; Satoh, K.; Iguchi, S.; Kikuchi, K.; Mimaki, M.; Makimura, K.
Rapid detection of Candida auris based on loop-mediated isothermal amplification (LAMP). J. Clin. Microbiol.
2018, 56. [CrossRef]
52. Kordalewska, M.; Zhao, Y.; Lockhart, S.R.; Chowdhary, A.; Berrio, I.; Perlin, D.S. Rapid and accurate
molecular identification of the emerging multidrug-resistant pathogen Candida auris. J. Clin. Microbiol. 2017,
55, 2445–2452. [CrossRef] [PubMed]
53. Leach, L.; Zhu, Y.; Chaturvedi, S. Development and validation of a real-time PCR assay for rapid detection
of Candida auris from surveillance samples. J. Clin. Microbiol. 2018, 56. [CrossRef] [PubMed]
54. Martinez-Murcia, A.; Navarro, A.; Bru, G.; Chowdhary, A.; Hagen, F.; Meis, J.F. Internal validation of
GPS() MONODOSE CanAur dtec-qPCR kit following the UNE/EN ISO/IEC 17025:2005 for detection of the
emerging yeast Candida auris. Mycoses 2018, 61, 877–884. [CrossRef] [PubMed]
55. Ruiz-Gaitan, A.C.; Fernandez-Pereira, J.; Valentin, E.; Tormo-Mas, M.A.; Eraso, E.; Peman, J.; de Groot, P.W.J.
Molecular identification of Candida auris by PCR amplification of species-specific GPI protein-encoding
genes. Int. J. Med. Microbiol. 2018, 308, 812–818. [CrossRef] [PubMed]
56. Sexton, D.J.; Kordalewska, M.; Bentz, M.L.; Welsh, R.M.; Perlin, D.S.; Litvintseva, A.P. Direct detection of emergent
fungal pathogen Candida auris in clinical skin swabs by SYBR Green qPCR assay. J. Clin. Microbiol. 2018. [CrossRef]
[PubMed]
57. Sexton, D.J.; Bentz, M.L.; Welsh, R.M.; Litvintseva, A.P. Evaluation of a new T2 Magnetic Resonance assay
for rapid detection of emergent fungal pathogen Candida auris on clinical skin swab samples. Mycoses 2018,
61, 786–790. [CrossRef] [PubMed]
58. Theill, L.; Dudiuk, C.; Morales-Lopez, S.; Berrio, I.; Rodriguez, J.Y.; Marin, A.; Gamarra, S.; Garcia-Effron, G.
Single-tube classical PCR for Candida auris and Candida haemulonii identification. Rev. Iberoam Micol. 2018, 35,
110–112. [CrossRef] [PubMed]
59. Hou, X.; Lee, A.; Jimenez-Ortigosa, C.; Kordalewska, M.; Perlin, D.S.; Zhao, Y. Rapid detection of
ERG11-associated azole resistance and FKS-associated echinocandin resistance in Candida auris. Antimicrob.
Agents Chemother. 2018. [CrossRef]
J. Fungi 2018, 4, 129 10 of 13
60. Cadnum, J.L.; Shaikh, A.A.; Piedrahita, C.T.; Jencson, A.L.; Larkin, E.L.; Ghannoum, M.A.; Donskey, C.J.
Relative resistance of the emerging fungal pathogen Candida auris and other Candida species to killing by
ultraviolet light. Infect. Control. Hosp. Epidemiol 2018, 39, 94–96. [CrossRef]
61. Kean, R.; Sherry, L.; Townsend, E.; McKloud, E.; Short, B.; Akinbobola, A.; Mackay, W.G.; Williams, C.;
Jones, B.L.; Ramage, G. Surface disinfection challenges for Candida auris: an in-vitro study. J. Hosp. Infect.
2018, 98, 433–436. [CrossRef]
62. Welsh, R.M.; Bentz, M.L.; Shams, A.; Houston, H.; Lyons, A.; Rose, L.J.; Litvintseva, A.P. Survival, persistence,
and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care
surface. J. Clin. Microbiol. 2017, 55, 2996–3005. [CrossRef] [PubMed]
63. Chowdhary, A.; Voss, A.; Meis, J.F. Multidrug-resistant Candida auris: ‘new kid on the block’ in
hospital-associated infections? J. Hosp. Infect. 2016, 94, 209–212. [CrossRef] [PubMed]
64. Meis, J.F.; Chowdhary, A. Candida auris: a global fungal public health threat. Lancet Infect. Dis. 2018, 18,
1298–1299. [CrossRef]
65. Kathuria, S.; Singh, P.K.; Sharma, C.; Prakash, A.; Masih, A.; Kumar, A.; Meis, J.F.; Chowdhary, A.
Multidrug-resistant Candida auris misidentified as Candida haemulonii: Characterization by matrix-assisted
laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal
susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J. Clin. Microbiol.
2015, 53, 1823–1830. [PubMed]
66. Kumar, A.; Prakash, A.; Singh, A.; Kumar, H.; Hagen, F.; Meis, J.F.; Chowdhary, A. Candida haemulonii species
complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and
amplified fragment-length polymorphism analyses. Emerg. Microbes Infect. 2016, 5, e49. [CrossRef] [PubMed]
67. Mizusawa, M.; Miller, H.; Green, R.; Lee, R.; Durante, M.; Perkins, R.; Hewitt, C.; Simner, P.J.; Carroll, K.C.;
Hayden, R.T.; et al. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology
laboratories? J. Clin. Microbiol. 2017, 55, 638–640. [CrossRef] [PubMed]
68. Prakash, A.; Sharma, C.; Singh, A.; Kumar Singh, P.; Kumar, A.; Hagen, F.; Govender, N.P.; Colombo, A.L.;
Meis, J.F.; Chowdhary, A. Evidence of genotypic diversity among Candida auris isolates by multilocus
sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified
fragment length polymorphism. Clin. Microbiol. Infect. 2016, 22, e271–e279. [CrossRef]
69. Arendrup, M.C.; Prakash, A.; Meletiadis, J.; Sharma, C.; Chowdhary, A. Comparison of EUCAST and CLSI
reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative
epidemiological cutoff values. Antimicrob. Agents Chemother. 2017, 61. [CrossRef]
70. Hyde, K.D.; Al-Hatmi, A.M.S.; Andersen, B.; Boekhout, T.; Buzina, W.; Dawson, T.L.; Eastwood, D.C.;
Jones, E.B.G.; de Hoog, S.; Kang, Y.; et al. The world’s ten most feared fungi. Fungal Diversity 2018.
[CrossRef]
71. Larkin, E.; Hager, C.; Chandra, J.; Mukherjee, P.K.; Retuerto, M.; Salem, I.; Long, L.; Isham, N.; Kovanda, L.;
Borroto-Esoda, K.; et al. The emerging pathogen Candida auris: Growth phenotype, virulence factors, activity
of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm
formation. Antimicrob. Agents Chemother. 2017, 61. [CrossRef]
72. Hager, C.L.; Larkin, E.L.; Long, L.A.; Ghannoum, M.A. Evaluation of the efficacy of rezafungin, a novel
echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse
model. J. Antimicrob. Chemother. 2018, 73, 2085–2088. [CrossRef]
73. Hager, C.L.; Larkin, E.L.; Long, L.; Zohra Abidi, F.; Shaw, K.J.; Ghannoum, M.A. In vitro and in vivo
evaluation of the antifungal activity of APX001A/APX001 against Candida auris. Antimicrob. Agents Chemother.
2018, 62. [CrossRef] [PubMed]
74. Fakhim, H.; Vaezi, A.; Dannaoui, E.; Chowdhary, A.; Nasiry, D.; Faeli, L.; Meis, J.F.; Badali, H. Comparative
virulence of Candida auris with Candida haemulonii, Candida glabrata and Candida albicans in a murine model.
Mycoses 2018, 61, 377–382. [CrossRef] [PubMed]
75. Adams, E.; Quinn, M.; Tsay, S.; Poirot, E.; Chaturvedi, S.; Southwick, K.; Greenko, J.; Fernandez, R.; Kallen, A.;
Vallabhaneni, S.; et al. Candida auris in Healthcare Facilities, New York, USA, 2013–2017. Emerg. Infect. Dis.
2018, 24, 1816–1824. [CrossRef] [PubMed]
76. Chatterjee, S.; Alampalli, S.V.; Nageshan, R.K.; Chettiar, S.T.; Joshi, S.; Tatu, U.S. Draft genome of a commonly
misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics 2015, 16, 686. [CrossRef] [PubMed]
J. Fungi 2018, 4, 129 11 of 13
77. Healey, K.R.; Kordalewska, M.; Jimenez Ortigosa, C.; Singh, A.; Berrio, I.; Chowdhary, A.; Perlin, D.S. Limited
ERG11 mutations identified in isolates of Candida auris directly contribute to reduced azole susceptibility.
Antimicrob. Agents Chemother. 2018, 62, e01427-18. [CrossRef] [PubMed]
78. Lepak, A.J.; Zhao, M.; Berkow, E.L.; Lockhart, S.R.; Andes, D.R. Pharmacodynamic optimization for treatment
of invasive Candida auris infection. Antimicrob. Agents Chemother. 2017, 61. [CrossRef] [PubMed]
79. Fakhim, H.; Chowdhary, A.; Prakash, A.; Vaezi, A.; Dannaoui, E.; Meis, J.F.; Badali, H. In vitro interactions
of echinocandins with triazoles against multidrug-resistant Candida auris. Antimicrob. Agents Chemother.
2017, 61. [CrossRef]
80. Kordalewska, M.; Lee, A.; Park, S.; Berrio, I.; Chowdhary, A.; Zhao, Y.; Perlin, D.S. Understanding
echinocandin resistance in the emerging pathogen Candida auris. Antimicrob. Agents Chemother. 2018, 62.
[CrossRef]
81. Arendrup, M.C.; Chowdhary, A.; Astvad, K.M.T.; Jorgensen, K.M. APX001A in vitro activity against
contemporary blood isolates and Candida auris determined by the EUCAST reference method. Antimicrob.
Agents Chemother. 2018, 62. [CrossRef]
82. Berkow, E.L.; Angulo, D.; Lockhart, S.R. In vitro activity of a novel glucan synthase inhibitor, SCY-078,
against clinical isolates of Candida auris. Antimicrob. Agents Chemother. 2017, 61. [CrossRef] [PubMed]
83. Berkow, E.L.; Lockhart, S.R. Activity of novel antifungal compound APX001A against a large collection of
Candida auris. J. Antimicrob. Chemother. 2018, 73, 3060–3062. [CrossRef] [PubMed]
84. Berkow, E.L.; Lockhart, S.R. Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida
auris. Diagn Microbiol. Infect. Dis. 2018, 90, 196–197. [CrossRef] [PubMed]
85. Lepak, A.J.; Zhao, M.; Andes, D.R. Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris
in the neutropenic mouse invasive candidiasis model. Antimicrob. Agents Chemother. 2018, 62. [CrossRef]
[PubMed]
86. Wiederhold, N.P.; Patterson, H.P.; Tran, B.H.; Yates, C.M.; Schotzinger, R.J.; Garvey, E.P. Fungal-specific
Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic
fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus. J. Antimicrob. Chemother.
2018, 73, 404–408. [CrossRef] [PubMed]
87. Break, T.J.; Desai, J.V.; Healey, K.R.; Natarajan, M.; Ferre, E.M.N.; Henderson, C.; Zelazny, A.; Siebenlist, U.;
Yates, C.M.; Cohen, O.J.; et al. VT-1598 inhibits the in vitro growth of mucosal Candida strains and
protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice.
J. Antimicrob. Chemother. 2018, 73, 2089–2094. [CrossRef] [PubMed]
88. Ku, T.S.N.; Walraven, C.J.; Lee, S.A. Candida auris: Disinfectants and implications for infection control.
Front. Microbiol. 2018, 9, 726. [CrossRef]
89. Moore, G.; Schelenz, S.; Borman, A.M.; Johnson, E.M.; Brown, C.S. Yeasticidal activity of chemical
disinfectants and antiseptics against Candida auris. J. Hosp. Infect. 2017, 97, 371–375. [CrossRef] [PubMed]
90. Abdolrasouli, A.; Armstrong-James, D.; Ryan, L.; Schelenz, S. In vitro efficacy of disinfectants utilised for
skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris.
Mycoses 2017, 60, 758–763. [CrossRef]
91. Denning, D.W.; Venkateswarlu, K.; Oakley, K.L.; Anderson, M.J.; Manning, N.J.; Stevens, D.A.;
Warnock, D.W.; Kelly, S.L. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother.
1997, 41, 1364–1368. [CrossRef]
92. Verweij, P.E.; Chowdhary, A.; Melchers, W.J.; Meis, J.F. Azole resistance in Aspergillus fumigatus: Can we
retain the clinical use of mold-active antifungal azoles? Clin. Infect. Dis. 2016, 62, 362–368. [CrossRef]
[PubMed]
93. Denning, D.W.; Perlin, D.S. Azole resistance in Aspergillus: a growing public health menace. Future Microbiol.
2011, 6, 1229–1232. [CrossRef] [PubMed]
94. van der Linden, J.W.; Arendrup, M.C.; Warris, A.; Lagrou, K.; Pelloux, H.; Hauser, P.M.; Chryssanthou, E.;
Mellado, E.; Kidd, S.E.; Tortorano, A.M.; et al. Prospective multicenter international surveillance of azole
resistance in Aspergillus fumigatus. Emerg. Infect. Dis. 2015, 21, 1041–1044. [CrossRef] [PubMed]
95. Meis, J.F.; Chowdhary, A.; Rhodes, J.L.; Fisher, M.C.; Verweij, P.E. Clinical implications of globally emerging
azole resistance in Aspergillus fumigatus. Philos Trans. R Soc. Lond B Biol. Sci. 2016, 371. [CrossRef] [PubMed]
96. Goncalves, S.S.; Souza, A.C.; Chowdhary, A.; Meis, J.F.; Colombo, A.L. Epidemiology and molecular
mechanisms of antifungal resistance in Candida and Aspergillus. Mycoses 2016. [CrossRef]
J. Fungi 2018, 4, 129 12 of 13
97. Mortensen, K.L.; Mellado, E.; Lass-Florl, C.; Rodriguez-Tudela, J.L.; Johansen, H.K.; Arendrup, M.C.
Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark,
and Spain. Antimicrob. Agents Chemother. 2010, 54, 4545–4549. [CrossRef] [PubMed]
98. Snelders, E.; Huis In ’t Veld, R.A.; Rijs, A.J.; Kema, G.H.; Melchers, W.J.; Verweij, P.E. Possible environmental
origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 2009, 75, 4053–4057.
[CrossRef]
99. Badali, H.; Vaezi, A.; Haghani, I.; Yazdanparast, S.A.; Hedayati, M.T.; Mousavi, B.; Ansari, S.; Hagen, F.;
Meis, J.F.; Chowdhary, A. Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H
mutations in the cyp51A gene in Iran. Mycoses 2013, 56, 659–663. [CrossRef]
100. Ozmerdiven, G.E.; Ak, S.; Ener, B.; Agca, H.; Cilo, B.D.; Tunca, B.; Akalin, H. First determination of azole
resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey. J. Infect. Chemother.
2015, 21, 581–586. [CrossRef]
101. Koehler, P.; Hamprecht, A.; Bader, O.; Bekeredjian-Ding, I.; Buchheidt, D.; Doelken, G.; Elias, J.; Haase, G.;
Hahn-Ast, C.; Karthaus, M.; et al. Epidemiology of invasive aspergillosis and azole resistance in patients
with acute leukaemia: the SEPIA Study. Int J. Antimicrob. Agents 2017, 49, 218–223. [CrossRef]
102. Resendiz Sharpe, A.; Lagrou, K.; Meis, J.F.; Chowdhary, A.; Lockhart, S.R.; Verweij, P.E.; ISHAM ECMM
Aspergillus Resistance Surveillance Working Group. Triazole resistance surveillance in Aspergillus fumigatus.
Med. Mycol. 2018, 56, 83–92. [CrossRef]
103. CLSI. CLSI Document M38-A2. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous
Fungi; Approved Standard-Second Edition; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2008.
104. Arendrup, M.C.; Meletiadis, J.; Mouton, J.W.; Lagrou, K.; Hamal, P.; Guinea, J.; Subcommittee on AFST of the
ESCMID for EUCAST. EUCAST Definitive Document E.DEF 9.3.1 Method for the Determination of Broth
Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Conidia Forming Moulds. Available
online: http://www.eucast.org/ast_of_fungi/methodsinantifungalsusceptibilitytesting/susceptibility_
testing_of_moulds/ (accessed on 1 November 2018).
105. Meletiadis, J.; Leth Mortensen, K.; Verweij, P.E.; Mouton, J.W.; Arendrup, M.C. Spectrophotometric reading
of EUCAST antifungal susceptibility testing of Aspergillus fumigatus. Clin. Microbiol. Infect. 2017, 23, 98–103.
[CrossRef] [PubMed]
106. Ullmann, A.J.; Aguado, J.M.; Arikan-Akdagli, S.; Denning, D.W.; Groll, A.H.; Lagrou, K.; Lass-Flörl, C.;
Lewis, R.E.; Munoz, P.; Verweij, P.E.; et al. Diagnosis and management of Aspergillus diseases: executive
summary of the 2017 ESCMID-ECMM-ERS guideline. Clin. Microbiol. Infect. 2018, 24, e1–e38. [CrossRef]
[PubMed]
107. Patterson, T.F.; Thompson, G.R., 3rd; Denning, D.W.; Fishman, J.A.; Hadley, S.; Herbrecht, R.;
Kontoyiannis, D.P.; Marr, K.A.; Morrison, V.A.; Nguyen, M.H.; et al. Practice guidelines for the diagnosis and
management of aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis.
2016, 63, e1–e60. [CrossRef] [PubMed]
108. CLSI. CLSI Document M51-A. Method for Antifungal Disk Diffusion Susceptibility Testing of Nondermatophyte
Filamentous Fungi; Approved Guideline; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2010.
109. Espinel-Ingroff, A.; Chowdhary, A.; Gonzalez, G.M.; Lass-Florl, C.; Martin-Mazuelos, E.; Meis, J.; Pelaez, T.;
Pfaller, M.A.; Turnidge, J. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff
values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob. Agents Chemother.
2013, 57, 3823–3828. [CrossRef] [PubMed]
110. Espinel-Ingroff, A.; Cuenca-Estrella, M.; Fothergill, A.; Fuller, J.; Ghannoum, M.; Johnson, E.;
Pelaez, T.; Pfaller, M.A.; Turnidge, J. Wild-type MIC distributions and epidemiological cutoff values
for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).
Antimicrob. Agents Chemother. 2011, 55, 5150–5154. [CrossRef]
111. Espinel-Ingroff, A.; Diekema, D.J.; Fothergill, A.; Johnson, E.; Pelaez, T.; Pfaller, M.A.; Rinaldi, M.G.;
Canton, E.; Turnidge, J. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and
six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 2010, 48,
3251–3257. [CrossRef]
112. CLSI. CLSI Document M59. Epidemiological Cutoff Values for Antifungal Susceptibility Testing, 1st ed.; Clinical
and Laboratory Standards Institute: Wayne, PA, USA, 2016.
113. EUCAST. Available online: http://www.eucast.org/ (accessed on 1 November 2018).
J. Fungi 2018, 4, 129 13 of 13
114. Arendrup, M.C.; Verweij, P.E.; Mouton, J.W.; Lagrou, K.; Meletiadis, J. Multicentre validation of 4-well azole
agar plates as a screening method for detection of clinically relevant azole-resistant Aspergillus fumigatus.
J. Antimicrob. Chemother. 2017, 72, 3325–3333. [CrossRef]
115. Guinea, J.; Verweij, P.E.; Meletiadis, J.; Mouton, J.W.; Barchiesi, F.; Arendrup, M.C.; Subcommittee on
Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility
Testing (EUCAST), EUCAST-AFST; Arendrup, M.C.; Arikan-Akdagli, S.; Barchiesi, F.; et al. How to: EUCAST
recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus
fumigatus isolates using four well azole-containing agar plates. Clin. Microbiol. Infect. 2018. [CrossRef]
116. Chowdhary, A.; Sharma, C.; Meis, J.F. Azole-resistant aspergillosis: Epidemiology, molecular mechanisms,
and treatment. J. Infect. Dis. 2017, 216, S436–S444. [CrossRef]
117. Alvarez-Moreno, C.; Lavergne, R.A.; Hagen, F.; Morio, F.; Meis, J.F.; Le Pape, P. Azole-resistant Aspergillus
fumigatus harboring TR34/L98H, TR46/Y121F/T289A and TR53 mutations related to flower fields in
Colombia. Sci Rep. 2017, 7, 45631. [CrossRef] [PubMed]
118. Hodiamont, C.J.; Dolman, K.M.; Ten Berge, I.J.; Melchers, W.J.; Verweij, P.E.; Pajkrt, D.
Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease
successfully treated with long-term oral posaconazole and surgery. Med. Mycol. 2009, 47, 217–220. [CrossRef]
[PubMed]
119. Abdolrasouli, A.; Rhodes, J.; Beale, M.A.; Hagen, F.; Rogers, T.R.; Chowdhary, A.; Meis, J.F.;
Armstrong-James, D.; Fisher, M.C. Genomic context of azole resistance mutations in Aspergillus fumigatus
determined using whole-genome sequencing. MBio 2015, 6, e00536. [CrossRef]
120. Deng, S.; Zhang, L.; Ji, Y.; Verweij, P.E.; Tsui, K.M.; Hagen, F.; Houbraken, J.; Meis, J.F.; Abliz, P.; Wang, X.;
et al. Triazole phenotypes and genotypic characterization of clinical Aspergillus fumigatus isolates in China.
Emerg. Microbes Infect. 2017, 6, e109. [CrossRef] [PubMed]
121. Snelders, E.; van der Lee, H.A.; Kuijpers, J.; Rijs, A.J.; Varga, J.; Samson, R.A.; Mellado, E.; Donders, A.R.;
Melchers, W.J.; Verweij, P.E. Emergence of azole resistance in Aspergillus fumigatus and spread of a single
resistance mechanism. PLoS Med. 2008, 5, e219. [CrossRef] [PubMed]
122. van der Linden, J.W.; Snelders, E.; Kampinga, G.A.; Rijnders, B.J.; Mattsson, E.; Debets-Ossenkopp, Y.J.;
Kuijper, E.J.; Van Tiel, F.H.; Melchers, W.J.; Verweij, P.E. Clinical implications of azole resistance in Aspergillus
fumigatus, The Netherlands, 2007–2009. Emerg. Infect. Dis. 2011, 17, 1846–1854. [CrossRef] [PubMed]
123. Lestrade, P.P.; Bentvelsen, R.G.; Schauwvlieghe, A.; Schalekamp, S.; van der Velden, W.; Kuiper, E.J.; van
Paassen, J.; van der Hoven, B.; van der Lee, H.A.; Melchers, W.J.G.; et al. Voriconazole resistance and mortality
in invasive aspergillosis: A multicenter retrospective cohort study. Clin. Infect. Dis. 2018. [CrossRef]
124. Chong, G.M.; van der Beek, M.T.; von dem Borne, P.A.; Boelens, J.; Steel, E.; Kampinga, G.A.; Span, L.F.;
Lagrou, K.; Maertens, J.A.; Dingemans, G.J.; et al. PCR-based detection of Aspergillus fumigatus Cyp51A
mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay(R) in 201 patients
with haematological disease suspected for invasive aspergillosis. J. Antimicrob. Chemother. 2016, 71, 3528–3535.
[CrossRef]
125. Heo, S.T.; Tatara, A.M.; Jimenez-Ortigosa, C.; Jiang, Y.; Lewis, R.E.; Tarrand, J.; Tverdek, F.; Albert, N.D.;
Verweij, P.E.; Meis, J.F.; et al. Changes in in vitro susceptibility patterns of Aspergillus to triazoles and
correlation with aspergillosis outcome in a tertiary care cancer center, 1999–2015. Clin. Infect. Dis. 2017, 65,
216–225. [CrossRef]
126. Verweij, P.E.; Ananda-Rajah, M.; Andes, D.; Arendrup, M.C.; Bruggemann, R.J.; Chowdhary, A.;
Cornely, O.A.; Denning, D.W.; Groll, A.H.; Izumikawa, K.; et al. International expert opinion on the
management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist. Updates 2015, 21–22,
30–40. [CrossRef]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
